Core Viewpoint - Aikang Group held a media briefing to address the incident involving Ms. Zhang, who claimed that her kidney cancer was not detected during ten years of health check-ups. The company asserts that there were no diagnostic errors or omissions in her health checks and has filed a lawsuit against her for defamation [2][4][15]. Group 1: Company Response - Aikang Group confirmed that there were no missed diagnoses or misdiagnoses in Ms. Zhang's health checks, and the company has taken legal action against her for spreading false information [2][4][15]. - The founder and CEO of Aikang Group emphasized the importance of health checks in early disease detection, stating that approximately 1.5 million cancer cases are identified through Aikang's services each year [4][5]. - The company highlighted that health checks are not equivalent to clinical diagnoses and are intended to guide patients to seek further medical evaluation if necessary [4][5]. Group 2: Incident Timeline and Findings - The timeline of events was reviewed, indicating that Ms. Zhang underwent a health check on October 9, 2023, where her report indicated potential issues with her kidneys and recommended further examinations [5][8]. - Aikang Group conducted internal and external reviews, confirming that the findings in Ms. Zhang's report were accurate and consistent with her ultrasound results [8][9]. - The company provided evidence of quality control in their testing processes and stated that all medical personnel are certified and comply with national regulations [9][11]. Group 3: Medical Expert Opinions - Medical experts clarified that the cancer marker CEA is not relevant for kidney cancer screening, as early diagnosis primarily relies on imaging techniques rather than blood tests [11][13]. - Experts also noted that there are currently no specific blood markers for early detection of kidney cancer, reinforcing the validity of Aikang's diagnostic approach [11][13]. - Aikang Group's medical professionals expressed concern over the misinformation spread by Ms. Zhang, which could undermine public trust in the healthcare system [14][15].

Core Viewpoint - The company has formally filed a lawsuit against Ms. Zhang for spreading false information about "fake health checkups" which has severely harmed the company's legal rights and reputation [1][2]. Group 1: Company Response - The company expresses deep sympathy for Ms. Zhang's illness but emphasizes that being ill should not justify defaming the company [1]. - The lawsuit is based on the premise that Ms. Zhang's actions have not only harmed the company but also undermined public trust in the entire health checkup industry [1]. - The company highlights its commitment to health management services over the past 20 years and the negative impact of Ms. Zhang's statements on its employees and clients [1]. Group 2: Industry Impact - The company asserts that both private health checkup centers and public hospitals share the responsibility of providing diverse health checkup services to the public [1]. - Ms. Zhang's allegations have the potential to create a trust crisis not only for private health checkup centers but also for the entire healthcare industry in China, including public hospitals [1].

一篇《女律师十年体检未有"患癌风险"预警，确诊已是肾癌晚期》的文章，正在将体检行业龙头爱康国宾拖入舆论的风暴，而这场风波也再次让公众对整 个民营体检行业守护健康的价值，产生严重的质疑。 舆论压力之下，爱康国宾在7月30日举行了媒体说明会。 而爱康集团创始人、董事长兼CEO张黎刚对此称，"大家想一下，大多数企业给员工做个体检，少的几百块，钱多的也就几千块钱，大家去医院看个病， 你要诊断某个病，你们问问自己，大概要花多少钱。当你指望说，一个几百块钱的体检能帮你什么病都查出来，而要查单一的病，多花几千几万块钱的时 候，你认为这样的情况存在吗?至于这样的模糊的原因，就是因为我们公众对于体检与看病，没有明确的边界，导致公众对体检有很多误解。" 此番回应，不仅让爱康国宾陷入巨大争议，更是再度将民营体检行业推上了口碑近乎崩盘的风口浪尖。 回到事件本身。从2013 年到 2023 年，女律师张晓玲在爱康国宾完成了十年体检，所有报告均显示 "正常"。直到 2024 年，她在其他医院被确诊癌症晚 期，历经九个月跨国治疗，付出了失去一个肾和腰椎终"右肾钙化灶"。回想2023年那次体检，张女士的报告已经提示了右肾钙化，她特意询问工作 ...

Core Viewpoint - The CEO of Aikang Group, Zhang Ligang, emphasized that low-cost health check-ups cannot be expected to detect all diseases, highlighting a misunderstanding among the public regarding the boundaries between health check-ups and medical diagnoses [2][4][6]. Group 1: Company Response and Legal Actions - Aikang Group has filed a lawsuit against lawyer Zhang Xiaoling regarding a dispute over health check-ups, which has gained public attention due to her late-stage kidney cancer diagnosis despite ten years of health check-ups with Aikang [4][5]. - Zhang Xiaoling has welcomed the lawsuit and plans to gather a team of lawyers to address issues of misdiagnosis and underdiagnosis in the health check-up industry, aiming to initiate a public interest lawsuit [5]. - Zhang Ligang stated that the responsibility for timely follow-ups lies with individuals, and the accusations against Aikang are damaging to the trust in the entire health check-up industry in China [6]. Group 2: Public Perception and Industry Implications - The public reaction includes skepticism about the effectiveness of Aikang's health check-ups, with some questioning the value of such services if they do not provide accurate early warnings for serious conditions [7]. - Concerns have been raised about the potential implications for the health check-up industry, as the case may lead to increased scrutiny and calls for regulatory changes to improve standards and accountability [5][6].

Core Insights - The application of AI technology is becoming a key solution to the dual challenges of uneven medical resource distribution and service efficiency bottlenecks in the healthcare industry [1][3] - The AI Intelligent Total Inspection Machine, developed by Shanzhen and ZTE, has achieved commercial deployment in collaboration with Shanghai Tenth People's Hospital, marking a new phase in the application of AI in healthcare [1][4] Group 1: AI Technology and Its Impact - The AI Intelligent Total Inspection Machine reduces the traditional report generation time from 10 minutes to 2 minutes, achieving an accuracy rate of 95%, thus significantly improving efficiency and precision in medical reporting [3][7] - The machine utilizes an innovative "generative + rules" dual-engine architecture, ensuring medical logic rigor while optimizing report readability, balancing technological advancement with medical safety [3][5] Group 2: Market Position and Competitive Advantage - Shanzhen's core competitive advantage lies in its comprehensive health check database and a network of 3,000 hospital clients, which supports continuous product optimization and rapid promotion [4][7] - The company has built a solid data barrier over more than a decade in the health check industry, transforming vast amounts of anonymized data into a core engine driving AI medical innovation [5][8] Group 3: Business Model Transformation - The business model of Shanzhen is shifting from traditional software sales to a data-driven health ecosystem, covering the entire health management process before, during, and after health checks [7][8] - The AI Intelligent Total Inspection Machine is expected to alleviate the long wait times for health check reports, enhancing user experience and making high-quality health check services accessible to users in lower-tier cities [7][8] Group 4: Future Outlook - The integration of AI technology into the health check industry, which has an annual scale of approximately 300 billion, is anticipated to bring profound changes, with 80% of the market being corporate group orders [8][9] - Shanzhen aims to leverage its industry experience, data technology, and capital advantages to drive a smart revolution in healthcare, with plans to apply AI technology in more personalized and precise health check services in the future [9]

7月30日，在媒体说明会上，爱康国宾董事长兼CEO张黎刚谈及国内癌症检出率：2022年数据显示，中 国14亿人口，每一年确诊癌症人数超480万，过去几年癌症确诊人数在不断上升，爱康国宾每年大概为 800万人提供体检服务，通过爱康体检发现、专科医院确诊的癌症患者超15000人。(新浪财经) ...

Core Viewpoint - The case of lawyer Zhang Xiaoling, who was diagnosed with late-stage kidney cancer after ten years of health check-ups at Aikang Guobin, raises serious concerns about the reliability of health check services in China, particularly regarding misdiagnosis and oversight in the industry [1][4][6]. Company Summary - Aikang Guobin has been a leading player in the health check industry, serving 1.483 million clients in Beijing alone from April 1, 2024, to March 31, 2025 [4]. - The company has faced increasing scrutiny and public backlash over allegations of "fake health checks" and misdiagnosis, with Zhang Xiaoling's case being particularly emblematic of these issues [4][6]. - Aikang Guobin's CEO, Zhang Ligang, previously criticized the industry for similar issues, which now seem to reflect back on his own company [4][8]. - The company has issued statements claiming that cancer detection is limited by time and equipment, and has denied any misdiagnosis or oversight [6][11]. Industry Summary - The health check industry is under intense scrutiny, with public trust eroding due to repeated allegations of misdiagnosis and oversight [5][10]. - Historical parallels are drawn to the infant formula scandal, emphasizing the need for accountability and quality assurance in health services [5]. - Complaints against Aikang Guobin have surged, with over 1,200 complaints reported on consumer platforms, indicating widespread dissatisfaction with service quality [8][9]. - The industry faces challenges related to quality control, with many institutions lacking proper medical testing standards and protocols, leading to potential health risks for consumers [20][22]. - The need for industry self-regulation and improved consumer education is highlighted, as many consumers are unaware of the limitations of certain health indicators used in screenings [21][23].

Macro Dynamics - In the first half of the year, China attracted foreign investment amounting to 423.23 billion RMB, a year-on-year decrease of 15.2% [1] - A total of 30,014 new foreign-invested enterprises were established, representing a year-on-year increase of 11.7% [1] - The manufacturing sector attracted 109.06 billion RMB, while the service sector attracted 305.87 billion RMB [1] - High-tech industries received 127.87 billion RMB in foreign investment, with significant growth in e-commerce services (127.1%), chemical pharmaceuticals (53%), aerospace manufacturing (36.2%), and medical equipment (17.7%) [1] - Investment from ASEAN countries increased by 8.8%, with Switzerland, Japan, the UK, Germany, and South Korea showing growth rates of 68.6%, 59.1%, 37.6%, 6.3%, and 2.7% respectively [1] Company Dynamics - Fidelity Fund Management (China) announced a change in chairmanship, with Li Shaojie taking over from Huang Xiaoyi due to personal reasons [5] - iKang Healthcare Group confirmed that it has completed an internal review and external expert evaluation, asserting no responsibility regarding a complaint about a late-stage cancer diagnosis [8] - Dongfang Hope denied allegations of selling polysilicon below cost, stating compliance with market rules and legal regulations [9] - NIO reported malicious online activities targeting the company and its employees, leading to a police report being filed against the perpetrators [10]

Group 1: Tax Policy Changes - The Ministry of Finance has adjusted the consumption tax policy for super luxury cars, expanding the scope to include passenger cars and light commercial vehicles with a retail price of 900,000 yuan (excluding VAT) and above, regardless of the type of power source [1] Group 2: Company Financial Performance - Jin Jiang International Hotel's first financial report after submitting its IPO application shows a projected net profit decline of over 50% for the first half of 2025, estimating a profit of 360 million to 400 million yuan, down from the previous year by 4.88 billion to 4.48 billion yuan, a year-on-year decrease of 57.53% to 52.81% [2] - ScaleAI plans to lay off approximately 200 full-time employees, which is 14% of its workforce, as part of a restructuring of its generative AI business [6] - Kingwise Technology has successfully won multiple projects from the State Grid and China Southern Power Grid, with a total bid amount of 133 million yuan [7] - Datang Power's electricity generation for the first half of 2025 increased by 1.30% year-on-year, totaling approximately 123.99 billion kWh, with wind and solar power generation rising by 31.27% and 36.35% respectively [8] - Jinduicheng Molybdenum's net profit for the first half of 2025 is reported at 1.38 billion yuan, a year-on-year decrease of 8.45% [9] - Zongheng Co. expects a revenue increase of 61.72% for the first half of 2025, projecting a revenue of 135 million yuan [10] - Xiamen Tungsten's net profit for the first half of 2025 is reported at 972 million yuan, a year-on-year decrease of 4.41% [11] Group 3: Market Trends - The ChiNext index experienced a rise of 1.76%, with significant gains in AI hardware and innovative pharmaceutical sectors, while traditional sectors like real estate and power saw declines [12]

来源：正在新闻 北京的执业律师张晓玲称她在爱康国宾设于北京的体检分院连续体检 10 年未被检出患癌风险，2024年 被发现患癌时已是晚期，她质疑爱康国宾体检涉嫌 " 误检、漏检 "。 随后，"爱康国宾CEO曾揭行业造假黑幕"相关话题引发网友热议，据智通财经报道，2018年，爱康国宾 CEO张黎刚曾公开爆料同行假体检。张黎刚称，一些同行"用护士假冒医生做超声检查"，"抽了血做都 不做，然后把血倒掉就出结果。"张黎刚称，一些机构敢于这么做是因为检出癌症的概率只有千分之 三。 张晓玲律师告诉《正在新闻》，"我现在看那篇报道，回过头来想，我觉得说的就是它自己，才能说出 那段话，不是他自己的话，他肯定评价不了别人，我也怀疑我的所有数据是假的，不然为什么十年都没 给我查出来，别人给我查出来了"。 张晓玲律师同时表示，爱康国宾方面昨天晚上委托律师找自己做了沟通，但没有实际内容，就表明会以 积极态度回应。 7月17日，爱康国宾代理律师吴律师告诉《正在新闻》，"我们昨天有联系张律师，对她律师函的内容， 我们这边正在搜集材料，也会尽快给到张律师这边回应。" 针对网友热议的爱康国宾CEO曾揭行业造假黑幕一事，吴律师回应称，"首先这 ...